Unlock stock picks and a broker-level newsfeed that powers Wall Street.
NasdaqGS - Delayed Quote USD

Insulet Corporation (PODD)

Compare
263.18
+0.57
+(0.22%)
At close: 4:00:00 PM EDT
263.18
0.00
(0.00%)
After hours: 4:05:11 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. James R. Hollingshead Ph.D. President, CEO & Director 2.88M -- 1963
Ms. Lauren Budden Group VP, Chief Accounting Officer & Controller 794.05k -- 1975
Mr. John Wodick Kapples J.D. Senior VP & General Counsel 1.02M -- 1960
Mr. Eric Benjamin Executive VP, Chief Product & Customer Experience Officer 1.14M -- 1983
Ms. Ana Maria Chadwick Executive VP, CFO & Treasurer -- -- 1972
Mr. Prem Singh Senior Vice President of Global Operations -- -- 1978
Mr. Amit Guliani Interim CTO & Group VP of Customer-Facing Software Engineering -- -- --
June Lazaroff Senior Director of Investor Relations -- -- --
Ms. Laetitia Cousin Senior VP of Regulatory Affairs, Quality Assurance & Compliance -- -- 1977
Ms. Angela Geryak Wiczek Senior Director of Corporate Communications -- -- --

Insulet Corporation

100 Nagog Park
Acton, MA 01720
United States
978 600 7000 https://www.insulet.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
3,900

Description

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Corporate Governance

Insulet Corporation’s ISS Governance QualityScore as of April 1, 2025 is 9. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 10; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

May 7, 2025 at 10:59 AM UTC - May 12, 2025 at 12:00 PM UTC

Insulet Corporation Earnings Date

Recent Events

March 21, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

March 18, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

March 17, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

March 10, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

February 21, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

February 20, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

December 10, 2024 at 10:30 AM UTC

at Nasdaq Investor Conference

December 4, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 8, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

November 7, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers